If you want to know which AI tools are worth your attention in the next 12 months, stop reading product reviews and start reading funding announcements — March 2026 just handed you a roadmap.
I run a site that reviews AI toolkits for a living. I test what works, flag what doesn’t, and try to save you the time of downloading yet another half-baked productivity app. But every few months, the funding data tells me more about where the space is going than any product demo ever could. March 2026 was one of those months.
OpenAI Keeps Pulling Away
OpenAI added roughly $10 billion to its already staggering raise in March, pushing its total funding past $120 billion. That number is almost too large to process practically. What it means for toolkit reviewers like me is simple: OpenAI’s APIs, models, and developer tools are not going anywhere. If you’re building a workflow around GPT-based tooling, the financial floor underneath that bet just got a lot thicker.
For context, Q1 2026 as a whole was dominated by the same names — OpenAI, Anthropic, xAI — which tells you that institutional money is concentrating, not spreading. The era of “throw $5M at 50 AI startups and see what sticks” appears to be giving way to fewer, much larger bets on established players.
The Two Raises I’m Actually Watching
OpenAI’s number grabs headlines, but two other March raises are more interesting to me from a toolkit perspective.
TENEX AI, out of Sarasota, Florida, pulled in $250 million in a Series B round focused on cybersecurity. That’s a serious check for a company most people outside the security space haven’t heard of yet. Cybersecurity AI is a category I’ve been watching closely because the tools in this space tend to be either genuinely useful or dangerously overconfident — there’s not much middle ground. A $250M Series B means TENEX is past the “interesting idea” stage. Expect a real product push, and expect me to get my hands on it when that happens.
eMed, based in Miami, raised $200 million in a Series A for health tech. A Series A at that size is notable. It signals that investors aren’t just interested in the concept — they’ve seen enough traction to write a very large early check. Health tech AI is a category where I’ve reviewed a lot of tools that promise clinical-grade results and deliver consumer-grade accuracy. Whether eMed breaks that pattern is something I’ll be watching.
Seed Stage Still Has a Pulse
Beyond the mega-rounds, the seed data from March is worth a look. RoboForce raised $52 million and UFORCE pulled in $50 million. These are robotics and workforce automation plays, and their seed sizes reflect how capital-intensive the hardware-adjacent AI space has become. A $50M seed round would have been a Series B just a few years ago.
The startup ai& also appeared in the seed data, which I’ll be honest — I know very little about yet. But it’s on my list.
What This Means for the Tools You’re Using Right Now
Here’s my practical read on all of this. The funding concentration in AI right now is creating a two-tier market. Tier one is the well-capitalized platforms — OpenAI, Anthropic, and their direct competitors — where you can reasonably expect continued development, support, and iteration. Tier two is everyone else, where the question isn’t just “does this tool work today” but “will this company exist in 18 months.”
When I review AI toolkits on this site, I already factor in funding health as part of the overall score. A tool built on a model from a company with $120 billion in backing is a different risk profile than one built on a model from a startup that raised $3 million in 2023 and has been quiet since.
The cybersecurity and health tech focus in March’s funding also tells me where the next wave of serious AI tools is coming from. These aren’t consumer apps. They’re enterprise and clinical products with real compliance requirements, which means if they work, they actually work — they’ve had to clear a much higher bar to get to market.
My Takeaway as a Reviewer
March 2026’s funding rounds didn’t surprise me, but they did sharpen my priorities. I’ll be paying closer attention to what TENEX AI ships, watching eMed’s product roadmap, and continuing to use OpenAI’s ecosystem as the baseline against which everything else gets measured. The money has spoken. Now we wait to see if the products follow.
🕒 Published: